Drug Approval | March 27, 2025
European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
ICMR will continue to track trends in HMPV circulation throughout the year
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
